An interventional study of Coffee and Control in Cardiovascular (CV) Risk, Cardiometabolic Risk Markers and Cognitive Assessment, sponsored by University of Reading. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Reading · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to investigate whether twelve weeks of daily coffee consumption can improve blood vessel elasticity (arterial stiffness) in adults typical of the UK population who are currently non-habitual coffee consumers. Additionally, the effects on cardiometabolic disease risk markers, liver health markers, cognitive function and inter-individual genetic variations in response to coffee consumption will be examined.
Coffee has gained interest for its role in the prevention of non-communicable diseases such as heart and liver disease. Observational studies have reported that regular coffee consumption (2-4 cups per day) is associated with reduced risk of cardiovascular disease, type 2 diabetes, and overall mortality. However, these observational studies do not prove direct causality, requiring the need for well-designed randomized controlled trials. Additionally, most evidence comes from habitual coffee drinkers, and there is limited understanding of whether introducing coffee to non-habitual consumers can provide similar health benefits, particularly in individuals that are typically reflective of the UK population.
This trial aims to provide direct causal evidence to the potential health effects of coffee consumption on risk markers for the development of cardiometabolic disease (such as type 2 diabetes, heart and liver diseases). To ensure the potential impact of habitual coffee consumption is minimised as a confounding factor, non-habitual coffee consumers (coffee-naïve) will be recruited. To maximise recruitment and adherence in the study, the coffee intervention is being provided in a tablet formulation (as opposed to a liquid drink formulation typical taken). In a previous pilot study conducted in 2025, the biological activity of the coffee tablet formulation is expected to be deemed bioequivalent compared to the liquid drink.
A 2-armed, double-blind, randomized controlled parallel trial will be conducted in participants that reflect the general population (estimated using UK representative data from the National Diet and Nutrition Survey). The primary outcome is the effect of coffee consumption on arterial stiffness (measured by cardio-ankle vascular index (CAVI)), an important prognostic marker of vascular aging and cardiovascular disease. Secondary outcomes will assess the impact of coffee consumption on cardiometabolic disease risk markers, liver health markers, cognitive function and genetic factors driving inter-individual response. This will be compared to a coffee-free control.
Study participation will require two visits to the Hugh Sinclair Unit of Human Nutrition (HSU), University of Reading, UK. For the first visit, participants will arrive having fasted overnight, consumed a standardised evening meal, and having followed lifestyle restrictions in the preceding days. Baseline anthropometric measures, blood pressure, CAVI measures, cognitive functions scores will be performed in addition to collecting a fasting blood sample (up to 50ml in total). Additionally, participants will be asked to provide a 24-hour urine sample during the same visit. At the end of the first study visit, participants will be randomised, stratified by age, gender and body-mass index (BMI), and receive their intervention bottles containing tablets to take on a daily basis over the 12-week study period. The second study visit will repeat the same procedures outlined at the end of 12 weeks.
University of Reading is the lead sponsor of 151 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will consume 5.4g of a commercially available instant coffee, provided in a tablet formulation (9 tablets daily).
Dietary Supplement: Coffee
This group will consume a coffee-free control, provided in a tablet formulation (9 tablets daily).
Dietary Supplement: Control
Commercially available instant coffee (5.4g), will be provided as 9 tablets (equivalent to 3 tablets per cup, therefore total 3 cups daily). This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.
Coffee-free control (microcrystallinecellulose (non-active)) will be provided as 9 tablets. This is to be consumed by the participant on a daily basis for 12 weeks. The intervention can be taken spaced throughout the day as per participant convenience, with a preference of consuming all 9 tablets by 2pm each day.
Cardio-ankle vascular index
Cardio-ankle vascular index (CAVI) score will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) and attachment of a PCG microphone (measuring heart sounds during the cardiac cycle) on the sternum using a VaSera VS-2000 device on study visits. No fixed scale range is present, lower scores indicate an improvement in outcome.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting coffee bioactives concentrations and polyphenol metabolite concentrations
Plasma concentrations of key coffee bioactives (e.g. caffeine, chlorogenic acids, trigonelline) and polyphenol metabolites will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry, concentration unit of measure (microgram per millilitre).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting lipid profile concentrations
Serum total cholesterol (TC), triacylglycerol, high-density lipoprotein cholesterol (HDL-C), non-esterified fatty acids and apolipoprotein B will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre). Low-density cholesterol concentrations will be calculated from TC concentrations and HDL-C concentrations using the Friedewald formula.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting insulin concentrations
Serum insulin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (IU per millilitre).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting glucose concentrations
Serum glucose will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (millimolar per millilitre).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting Haemoglobin A1C concentrations of glycaemic control measures
Haemoglobin (Hb) A1C will be measured from a fasting whole blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (%).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting estimate of insulin resistance
HOMA-IR (Homeostasis model assessment estimated insulin resistance) will be calculated using the fasting glucose and insulin data. Scale range: \<1 - 5+, lower scores indicate an improvement in outcome.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting estimate of insulin sensitivity
QUICKI (Quantitative Insulin Sensitivity Check Index) will be calculated using the fasting glucose and insulin data. Scale range: \<0.25 - 0.45+, higher scores indicate an improvement in outcome.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting liver enzyme and function concentrations
Serum alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transferase (AST), gamma-glutamyl transferase (GGT) and total bilirubin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (unit per liter).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting concentrations of kidney function measures
Serum uric acid and creatinine will be measured from a fasting blood sample collected on study visits. These samples will be analysed via clinical chemistry analyser, concentration unit of measure (micromolar per litre).
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting concentrations of inflammatory markers
Serum interleukin (IL) 1b, IL-6, high sensitivity C-reactive protein, tumour necrosis factor alpha, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay, concentration unit of measure (picogram per millilitre)
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting brain-derived neurotrophic factor concentrations
Serum brain-derived neurotrophic factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting vascular endothelial growth factor concentrations
Serum vascular endothelial growth factor will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting oxidised low density lipoprotein cholesterol concentrations
Plasma concentrations of oxidised low density cholesterol will be measured from a fasting blood sample collected on study visits. These samples will be analysed via automated enzyme-linked immunosorbent assay.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting trimethylamine N-oxide concentrations
Plasma concentrations of trimethylamine N-oxide will be measured from a fasting blood sample collected on study visits. These samples will be analysed via liquid chromatography mass spectrometry.
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting gut hormone concentrations
Plasma concentrations of C-peptide, gastric inhibitory polypeptide, glucagon-like receptor-1 and ghrelin will be measured from a fasting blood sample collected on study visits. These samples will be analysed via Luminex
Time frame: Week 0 (baseline), Week 12 (final visit)
Fasting estimated nitric oxide concentrations
Plasma estimated concentrations of nitric oxide (nitrate and nitrite) will be measured from a fasting blood sample collected on study visits. These samples will be analysed via chemiluminescence/LCMS.
Time frame: Week 0 (baseline), Week 12 (final visit)
Urinary metabolomics
Untargeted metabolomics will be performed on pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy
Time frame: Week 0 (baseline), Week 12 (final visit)
Urinary creatinine concentrations
Urinary concentrations of creatinine will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via clinical chemistry analyser
Time frame: Week 0 (baseline), Week 12 (final visit)
Urinary F2-isoprostanes concentrations
Urinary concentrations of F2-isoprostanes will be measured from pooled 24 hour urine samples collected on day prior to study visits. These samples will be analysed via liquid chromatography mass spectrometry.
Time frame: Week 0 (baseline), Week 12 (final visit)
Identification of gut microbiota composition
Gut microbiome composition will be identified and assessed using RNA sequencing from a stool sample, provided on day prior to study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Cognitive function
Assessment of cognitive function will be performed using Millisecond Inquisit 7 software on study visits. No fixed scale range is present, higher scores indicate an improvement in outcome.
Time frame: Week 0 (baseline), Week 12 (final visit)
Clinic blood pressure
Blood pressure will be measured using a blood pressure monitor on study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Ankle Brachial Index
Ankle Brachial Index will be measured by the attachment of an inflatable blood pressure cuff to each limb (right brachial, left brachial, right ankle, left ankle) using a VaSera VS-2000 device on study visits. Scale range: \<0.5 - 1.4+, higher scores indicate an improvement in outcome.
Time frame: Week 0 (baseline), Week 12 (final visit)
Lean body mass
Body lean mass will be measured by bioelectrical impedance using the Tanita scale on study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Body fat percentage
Body fat percentage will be measured by bioelectrical impedance using the Tanita scale on study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Body-mass index
Height will be measured using a stadiometer on the first study visit. Weight will be measured using the Tanita scale on both study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Hip and waist circumference
Hip and waist circumference will be measured using a non-stretch tape on study visits.
Time frame: Week 0 (baseline), Week 12 (final visit)
Plan to share: Yes — All anonymised IPD that underlie results in a publication and analytical code for statistical analysis
Supporting information: Study protocol, Analytic code
Time frame: Anonymised data will be made available on reasonable request to the study Chief Investigator one year after manuscripts have been published.
Access criteria: For data sharing and preservation, anonymised IPD will be archived in the University of Reading Research Data Archive. Access will be overseen by the project Chief Investigator (Associate Professor Charlotte Mills).
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Coffee